Novosibirsk · Russian-qualified counsel Recognised by Pravo-300 · Best Lawyers · Kommersant
Corporate & Regulatory

Regulatory update: technical regulation and product certification in Kazakhstan in the pharmaceuticals sector

Aigerim Serikbayeva · January 2026 · 8 min read

Kazakhstan tightened pharmaceutical certification rules under EAEU technical regulations. What foreign manufacturers need to do before the deadlines. Make an enquiry.

Following amendments that aligned Kazakhstan's pharmaceutical regulatory framework more closely with unified EAEU technical regulations, foreign manufacturers supplying or seeking to supply medicinal products to the Kazakhstani market face a materially changed compliance environment. The shifts affect registration procedures, GMP certification requirements, and the conditions under which existing marketing authorisations remain valid. For in-house counsel and regulatory affairs teams at companies with established or prospective Kazakhstan operations, understanding the sequencing of these changes — and the administrative timelines attached to them — is the immediate practical priority.

What has changed in Kazakhstan's pharmaceutical regulatory framework?

Kazakhstan's approach to pharmaceutical oversight has, for an extended period, operated along two parallel tracks: the national registration system administered by the authorised body for health care, and the EAEU-level market authorisation pathway established under EAEU supranational legislation. The practical coexistence of these tracks created compliance ambiguity for foreign manufacturers, particularly on the question of which GMP standards applied to a given product, which inspection body held authority, and whether a certificate issued under one system sufficed for the other.

The principal change now operative is the consolidation of pharmaceutical technical regulation under the EAEU's unified regulatory instrument for medicinal products. This consolidation resolves much of the earlier ambiguity in favour of the EAEU pathway — meaning that marketing authorisations issued through the national route are subject to defined transition timelines before they must be converted to or supplemented by EAEU-compliant registration. For companies currently relying on nationally issued marketing authorisations, this transition is not optional: authorisations that are not brought into conformity within the applicable window will cease to constitute a valid legal basis for market supply.

GMP compliance verification has similarly shifted. The recognised basis for GMP certification is now the EAEU GMP standard, and the inspection and certification authority is the Kazakhstani body operating within the EAEU's mutual recognition framework. Foreign manufacturers whose GMP certificates were issued by EU, US, or other non-EAEU regulatory bodies must understand that, while these certificates retain relevance to the dossier assessment process, they do not substitute for an EAEU GMP certificate where one is required by the applicable technical regulation.

The product dossier requirements have also been updated in line with EAEU Common Technical Document (CTD) format expectations. Companies that registered products under earlier national format requirements should anticipate that renewal or variation applications will require reformatting of the technical dossier to meet current standards.

Which foreign companies are most affected by these requirements?

The companies facing the most direct and immediate compliance exposure fall into three categories.

First, foreign manufacturers that hold nationally issued marketing authorisations for medicinal products currently distributed in Kazakhstan. These companies are subject to transition deadlines that are now running. The practical risk is not abstract: a failure to initiate conversion proceedings in time means that the legal basis for continued distribution lapses, requiring either a temporary halt to supply or emergency re-registration — neither of which is administratively simple. Foreign companies that manage Kazakhstan compliance as a secondary function within a broader regional regulatory programme, rather than as a standalone obligation, are particularly prone to missing these deadlines.

Second, foreign manufacturers planning new market entries into Kazakhstan in the pharmaceuticals sector. The unified EAEU pathway is, in principle, more predictable than the earlier national system — but only for companies that understand its procedural architecture. The dossier requirements, the local representative obligation, the role of the authorised body in dossier assessment, and the relationship between the EAEU registration and national post-registration obligations all require careful navigation. Companies that approach Kazakhstan as a straightforward extension of their EAEU strategy may find that national-level implementation rules introduce complications that were not apparent at the supranational level.

Third, distributors and contract manufacturers operating under agency or toll-manufacturing arrangements with foreign principals. Where the foreign principal holds the marketing authorisation, the compliance obligation rests with the authorisation holder — but the practical consequence of a lapsed authorisation falls on the in-country distributor, whose ability to supply the market is directly dependent on the authorisation remaining valid.

Under Kazakhstan's regulatory framework, penalties for supplying medicinal products without a valid marketing authorisation are substantial, and enforcement by the authorised body has become more systematic in recent years. Foreign companies that have not conducted a current-status review of their Kazakhstan pharmaceutical registrations since the EAEU consolidation took effect should do so without further delay.

What should foreign companies do now?

The immediate actions for foreign companies depend on their current market position, but a common framework applies across most situations.

The first step is a registration audit: a structured review of every marketing authorisation the company holds (or relies upon through a distribution arrangement) in Kazakhstan, confirming the basis of each authorisation, its current validity period, and whether it has been issued under the national or the EAEU pathway. This audit should also capture any pending renewal or variation applications, since these interact with the transition timeline in ways that can accelerate or complicate the conversion obligation.

The second step is GMP certificate status confirmation. Foreign manufacturers should identify, for each relevant manufacturing site, whether a current EAEU GMP certificate exists, whether an EAEU GMP inspection has been initiated, and what the lead time is for completing certification. GMP inspection scheduling in Kazakhstan and across the EAEU can run to several months; companies that begin this process only once a deadline is imminent are likely to encounter gaps in their authorisation chain.

The third step is local representative verification. Kazakhstan requires that a marketing authorisation holder be either a Kazakhstani legal entity or a foreign entity with a duly appointed local representative. The representative is legally responsible for a range of post-registration obligations — pharmacovigilance reporting, label compliance, recall coordination. Companies that established representative arrangements under the earlier national framework should verify that these arrangements remain adequate under current requirements, particularly where the representative's obligations have expanded as a result of the EAEU consolidation.

Where a company is at an early stage of market entry planning, the appropriate sequence is different: the correct starting point is a pre-submission regulatory assessment, which maps the registration pathway, identifies the applicable technical regulation requirements for the specific product category, and determines whether any national-level implementing measures create obligations beyond those in the EAEU base regulation.

The Regulatory & Licensing practice for Kazakhstan is positioned to support both the audit and the pre-submission stages. For companies with parallel market entry considerations — corporate structuring, distribution arrangements, or employment and migration issues arising from establishing a local presence — the Market Entry & Company Formation, Distribution & Franchising, and Employment & Migration pages set out the firm's work in each area.

Open questions and pending implementation

One area of genuine uncertainty concerns the treatment of combination products and medical devices with medicinal product characteristics — a category that sits at the boundary of pharmaceutical technical regulation and the EAEU's separate technical regulation on medical devices. The applicable registration pathway for these products has not been uniformly resolved in Kazakhstani administrative practice, and companies with products in this category should proceed on the basis that the authorised body may request clarification of the regulatory route before accepting a dossier.

A second open question concerns mutual recognition of marketing authorisations between EAEU member states — specifically, the extent to which a marketing authorisation obtained through the EAEU mutual recognition or decentralised procedure in one member state simplifies or accelerates the process in Kazakhstan. The formal framework supports reliance on such procedures, but the pace and completeness of implementation varies, and foreign companies should not assume that a successful registration in Russia or Armenia automatically translates into a predictable Kazakhstan timeline.

Companies operating in the Uzbekistan market simultaneously may also find it useful to consider the comparable Regulatory & Licensing framework for that jurisdiction, given that Uzbekistan has its own regulatory alignment process currently underway, though outside the EAEU.

"Kazakhstan's EAEU consolidation resolves longstanding ambiguity about which certification track applies — but it compresses the administrative window for companies that have not yet initiated conversion of nationally issued authorisations." — Aigerim Serikbayeva, Contributing Regional Analyst — Kazakhstan · EAEU trade, customs and market entry

Frequently asked questions

Q: What specifically changed in Kazakhstan's pharmaceutical certification and registration rules under the EAEU consolidation?

A: The principal change is that Kazakhstan has aligned its pharmaceutical marketing authorisation system with the unified EAEU regulatory framework for medicinal products. Nationally issued marketing authorisations are subject to defined transition timelines after which they must be converted to or supplemented by an EAEU-compliant registration to remain a valid legal basis for supply. GMP certification is now assessed against the EAEU GMP standard, and product dossiers must conform to EAEU Common Technical Document format requirements. Companies that registered products under the earlier national system and have not updated their registration status are likely to be in a transition period that is already running.

Q: Which foreign pharmaceutical companies are most directly affected by these changes, and what is the principal compliance risk?

A: The most directly affected companies are foreign manufacturers holding nationally issued Kazakhstani marketing authorisations that have not yet been converted, foreign companies planning new product registrations in Kazakhstan, and distributors whose supply position depends on a foreign principal's authorisation remaining valid. The principal compliance risk is that a marketing authorisation issued under the pre-consolidation national framework lapses — either because the transition deadline passes without conversion, or because a renewal or variation application does not meet current dossier standards. The consequence is loss of the legal basis for continued market supply, with enforcement exposure that has become more systematic under current Kazakhstani regulatory practice.

Practitioner note

This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.

Facing a matter like this?

Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.

Make an enquiry